We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$580M
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+15.91%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$216M
AUM Growth
+$6.19M
(+2.9%)
Cap. Flow
-$26.1M
Cap. Flow
% of AUM
-12.07%
Top 10 Holdings %
Top 10 Hldgs %
57.5%
Holding
62
New
15
Increased
10
Reduced
17
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$7.7M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$6.63M |
| 3 |
Prothena Corp
PRTA
|
+$6.46M |
| 4 |
Organogenesis Holdings
ORGO
|
+$6.4M |
| 5 |
INOV
Inovalon Holdings, Inc. Class A Common Stock
INOV
|
+$4.93M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$13.5M |
| 2 |
uniQure
QURE
|
+$4.96M |
| 3 |
Centene
CNC
|
+$4.95M |
| 4 |
AC Immune
ACIU
|
+$4.66M |
| 5 |
Iovance Biotherapeutics
IOVA
|
+$3.97M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.72% |
| 2 | Miscellaneous | 8.38% |
| 3 | Technology | 3.62% |
| 4 | Energy | 0.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
CALL
Prothena Corp
PRTA
$479M
| $2.1M | 0.97% |
+175,200
| New | +$2.07M |
|
|
27
uniQure
QURE
$3.38B
| $1.95M | 0.9% |
53,900
-117,529
| -69% | -$4.96M |
|
28
ADMA Biologics
ADMA
$2.09B
| $1.72M | 0.8% |
883,214
+347,890
| +65% | +$731K |
|
29
PUT
Veracyte
VCYT
$3.48B
| $1.71M | 0.79% |
+35,000
| New | +$1.62M |
|
|
RETA
30
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $1.5M | 0.69% |
12,112
-102,442
| -89% | -$13.5M |
|
31
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2B
| $1.41M | 0.65% |
+10,000
| New | +$1.28M |
|
|
ARNA
32
CALL
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $1.38M | 0.64% |
+18,000
| New | +$1.35M |
|
33
Immatics
IMTX
$1.44B
| $1.13M | 0.52% |
104,999
-8,461
| -7% | -$89.2K |
|
34
ProQR Therapeutics
PRQR
$323M
| $1.07M | 0.49% |
+255,000
| New | +$1.08M |
|
35
Mirum Pharmaceuticals
MIRM
$5.94B
| $1.05M | 0.49% |
+60,250
| New | +$1.18M |
|
36
Dianthus Therapeutics
DNTH
$5.92B
| $985K | 0.46% |
7,853
-7,413
| -49% | -$840K |
|
37
PUT
ARK Genomic Revolution ETF
ARKG
$1.88B
| $933K | 0.43% |
+10,000
| New | +$797K |
|
38
PUT
Beam Therapeutics
BEAM
$3.03B
| $816K | 0.38% |
+10,000
| New | +$492K |
|
|
AKU
39
DELISTED
Akumin Inc
AKU
| $675K | 0.31% |
+224,273
| New | +$752K |
|
|
LHCG
40
DELISTED
LHC Group LLC
LHCG
| $586K | 0.27% |
+2,746
| New | +$585K |
|
|
41
AC Immune
ACIU
$263M
| $46K | 0.02% |
8,942
-914,175
| -99% | -$4.66M |
|
42
Moderna
MRNA
$55.1B
| $18K | 0.01% |
+174
| New | +$17.6K |
|
43
Amneal Pharmaceuticals
AMRX
$6.11B
| – | – |
-512,659
| Closed | -$1.99M |
|
44
BioXcel Therapeutics
BTAI
$5.68M
| – | – |
-1,863
| Closed | -$1.29M |
|
|
CLLS
45
Cellectis
CLLS
$342M
| – | – |
-185,180
| Closed | -$3.43M |
|
46
Establishment Labs
ESTA
$2.11B
| – | – |
-86,042
| Closed | -$1.59M |
|
47
Gyre Therapeutics
GYRE
$699M
| – | – |
-40,224
| Closed | -$1.3M |
|
|
48
Iovance Biotherapeutics
IOVA
$3.63B
| – | – |
-120,606
| Closed | -$3.97M |
|
49
OrthoPediatrics
KIDS
$617M
| – | – |
-8,399
| Closed | -$386K |
|
50
Kura Oncology
KURA
$1.13B
| – | – |
-107,367
| Closed | -$3.29M |
|
Similar funds
SC
CCWM
CMA
RIS
MFS
GFI
PWM
CA
Prosight Management's Q4 2020 Portfolio in Review
As of Q4 2020, Prosight Management held 62 positions worth $216M, up 2.9% from $210M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Prosight Management withdrew a net $26.1M in Q4 2020, closing 20 positions and reducing 17 holdings. Its most notable exit was Iovance Biotherapeutics, an estimated $3.97M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 92% a quarter earlier, followed by Miscellaneous and Technology.
Against the trend, Prosight Management opened a new position in Vertex Pharmaceuticals worth $6.83M.
- Prosight Management's largest Q4 2020 buy was Vertex Pharmaceuticals: 28,900 shares worth $6.83M.
- Prosight Management added most to Alexion Pharmaceuticals in Q4 2020, an estimated $7.7M increase.
- Prosight Management's biggest Q4 2020 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $13.5M.
- Prosight Management fully exited Iovance Biotherapeutics in Q4 2020, selling an estimated $3.97M.
- Prosight Management's ten largest holdings make up 57% of its $216M portfolio in Q4 2020.
- Prosight Management opened 15 new positions and closed 20 in Q4 2020.
- Prosight Management's portfolio value rose 2.9% quarter-over-quarter to $216M.
Based on Prosight Management's 13F filing for Q4 2020, filed 12 Feb 2021.